Pulmocide is pleased to announce another PC945 publication in Antimicrobial Agents and Chemotherapy. The publication is available to download from the link below: AAC.ASM.ORG or the PDF can be downloaded […]
Pulmocide gave an oral presentation at Annual Conference of Microbiology society 2017, held on April 02-06, 2017 in Edinburgh in UK. Title was: Preclinical characterization of PC786, a novel inhaled […]
26 April 2017
Pulmocide is pleased to announce a PC945 publication in Antimicrobial Agents and Chemotherapy. The Publication is available to download from the link below Download or can be found online at […]
26 April 2017
Funding to progress novel wholly-owned compounds for RSV and pulmonary Aspergillosis London, UK, 20 March 2017: Pulmocide Ltd, the UK-based drug discovery company developing novel compounds designed for inhaled […]
20 March 2017
Pulmocide presented two posters at the IDweek 2016, held October 26 – 30, 2016 in New Orleans, LA. These are as follows: Anti-viral activities of PC786, a novel inhibitor […]
08 November 2016
Pulmocide gave an oral presentation (as a late breaking abstract) at European respiratory society annual meeting 2016, held September 03 – 07, 2016 in London, UK. This is as follows: […]
04 October 2016
Pulmocide presented two posters at the Macrae Foundation’s XVIII International Symposium on Respiratory Viral Infections, held March 31 – April 02, 2016 in Lisbon, Portugal. These are as follows: […]
04 April 2016
Pulmocide presented five posters at the recent 7th Advances Against Aspergillosis Conference in Manchester, and the meeting organisers published a Press Release about the work Pulmocide presented, stating: “Dr Kazuhiro Ito from Pulmocide, […]
07 March 2016
Pulmocide will present biological profile of First-in-Class inhaled anti-fungal agent, PC945 and PC1244 on upcoming 7th Advances against Aspergillosis in Manchester UK held March 3rd – 5th. http://www.advancesagainstaspergillosis.org/2016/programme.htm
15 January 2016